Semaglutide Linked to Reduced Risk of Alzheimer’s Disease in Diabetic Patients
(Source: Indian Express; Section: Explained; Page: 19) Topic: GS3 – Science & Technology Context: A recent study published in Alzheimer’s & Dementia reveals that semaglutide, a GLP-1 receptor agonist used in diabetes management, may reduce Alzheimer’s disease (AD) risk by up to 70% in individuals with type 2 diabetes. This finding positions semaglutide as potentially…